Saturday, December 4, 2021

GERMAN STUDY: Low Risk of Hospitalization, Severe Disease, and Mortality Due to CV and PIMS-TS in Children

Source: Med RXIV

Published: November 1, 2021

By: AL Sorg, M Hufnagel, M Doenhardt, N Diffloth, H Schroten, R v. Kries, R Berner, J Armann

Risk of Hospitalization, Severe Disease, and Mortality Due to CV and PIMS-TS in Children with SARS-CoV-2 Infection in Germany

This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.

Background: Although children and adolescents have a lower burden of SARS-CoV-2-associated disease as compared to adults, assessing absolute risk among children remains difficult due to a high rate of undetected cases. However, without more accurate case numbers, reliable risk analyses are impossible.

Methods: We combine data from three sources — a national seroprevalence study (the SARS-CoV-2 KIDS study), the German statutory notification system and a nationwide registry on children and adolescents hospitalized with either SARS-CoV-2 or Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) — in order to provide reliable estimates on children’s hospitalization, intensive care admission and death due to COVID-19 and PIMS-TS.

Results: While the overall hospitalization rate associated with SARS-CoV-2 infection was 35.9 per 10,000 children, ICU admission rate was 1.7 per 10,000 and case fatality was 0.09 per 10,000. Children without comorbidities were found to be significantly less likely to suffer from a severe or fatal disease course. The lowest risk was observed in children aged 5-11 without comorbidities. In this group, the ICU admission rate was 0.2 per 10,000 and case fatality could not be calculated, due to an absence of cases. The overall PIMS-TS rate was 1 per 4,000 SARS-CoV-2 infections, the majority being children without comorbidities.

Conclusion: Overall, the SARS-CoV-2-associated burden of a severe disease course or death in children and adolescents is low. This seems particularly the case for 5-11-year-old children without comorbidities. By contrast, PIMS-TS plays a major role in overall disease burden among all pediatric age groups.

Read more at:
Discerning the Mystery is a website dedicated to awakening and educating the people to their true potential of mental, spiritual, emotional, and physical growth. It can be difficult work, but if just one person benefits from these efforts, it is entirely worth it. 

If you enjoy what you read here, please give the post a like and share on social media. Also, if you enjoyed this article, please consider leaving a donation.

Feel free to send us an email and tell us what you think. If you have any suggestions or subjects you would like to see discussed, please let us know.

Thank you for your support.

No comments:

Post a Comment